Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab

To evaluate metrics that describe changes in apparent diffusion coefficient (ADC) and to examine their association with clinical outcome for patients with newly diagnosed GBM who were participating in a Phase II clinical trial of treatment with radiation (RT), temozolomide, erlatonib and bevacizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Qiuting, Jalilian, Laleh, Lupo, Janine M., Molinaro, Annette M., Chang, Susan M., Clarke, Jennifer, Prados, Michael, Nelson, Sarah J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311062/
https://www.ncbi.nlm.nih.gov/pubmed/25351579
http://dx.doi.org/10.1007/s11060-014-1636-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311062/
https://www.ncbi.nlm.nih.gov/pubmed/25351579
http://dx.doi.org/10.1007/s11060-014-1636-6

Ejemplares similares